Literature DB >> 20818795

Considerations on discontinuing natalizumab for the treatment of multiple sclerosis.

Joseph R Berger, Diego Centonze, Giancarlo Comi, Christian Confavreux, Gary Cutter, Gavin Giovannoni, Ralf Gold, Hans-Peter Hartung, Fred Lublin, Augusto Miravalle, Xavier Montalban, Paul O'Connor, Tomas Olsson, Chris H Polman, Olaf Stuve, Jerry S Wolinsky, Tjalf Ziemssen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20818795     DOI： 10.1002/ana.22083

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  15 in total

1.  Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.

Authors:  Marta Melis; Eleonora Cocco; Jessica Frau; Lorena Lorefice; Giuseppe Fenu; Giancarlo Coghe; Marco Mura; Maria Giovanna Marrosu
Journal:  Neurol Sci       Date:  2013-08-30       Impact factor: 3.307

Review 2.  A critical appraisal of treatment decisions in multiple sclerosis--old versus new.

Authors:  Bernd C Kieseier; Olaf Stüve
Journal:  Nat Rev Neurol       Date:  2011-04-05       Impact factor: 42.937

Review 3.  Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients.

Authors:  Tjalf Ziemssen; Raimar Kempcke; Marco Eulitz; Lars Großmann; Alexander Suhrbier; Katja Thomas; Thorsten Schultheiss
Journal:  J Neural Transm (Vienna)       Date:  2013-06-01       Impact factor: 3.575

4.  Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.

Authors:  Francesco Patti; Salvatore Lo Fermo
Journal:  Autoimmune Dis       Date:  2011-03-15

5.  IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. December 5-9, 2010, San Diego, CA USA.

Authors:  Samantha O Arnett; Jean-Luc Teillaud; Theirry Wurch; Janice M Reichert; Cameron Dunlop; Michael Huber
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

6.  CD4 cell response to interval therapy with natalizumab.

Authors:  Regina Berkovich; Daniel M Togasaki; Steven Y Cen; Lawrence Steinman
Journal:  Ann Clin Transl Neurol       Date:  2015-03-06       Impact factor: 4.511

7.  PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.

Authors:  Clara G Chisari; Giancarlo Comi; Massimo Filippi; Damiano Paolicelli; Pietro Iaffaldano; Mauro Zaffaroni; Vincenzo Brescia Morra; Eleonora Cocco; Girolama Alessandra Marfia; Luigi Maria Grimaldi; Matilde Inglese; Simona Bonavita; Alessandra Lugaresi; Giuseppe Salemi; Giovanna De Luca; Salvatore Cottone; Antonella Conte; Patrizia Sola; Umberto Aguglia; Giorgia Teresa Maniscalco; Claudio Gasperini; Maria Teresa Ferrò; Ilaria Pesci; Maria Pia Amato; Marco Rovaris; Claudio Solaro; Giacomo Lus; Davide Maimone; Roberto Bergamaschi; Franco Granella; Alessia Di Sapio; Antonio Bertolotto; Rocco Totaro; Marika Vianello; Paola Cavalla; Paolo Bellantonio; Vito Lepore; Francesco Patti
Journal:  J Neurol       Date:  2021-06-28       Impact factor: 4.849

Review 8.  Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2013-09       Impact factor: 11.431

Review 9.  Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.

Authors:  Renaud A Du Pasquier; Daniel D Pinschewer; Doron Merkler
Journal:  CNS Drugs       Date:  2014-06       Impact factor: 5.749

10.  Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers.

Authors:  Marianna Lo Re; Marco Capobianco; Paolo Ragonese; Sabrina Realmuto; Simona Malucchi; Paola Berchialla; Giuseppe Salemi; Antonio Bertolotto
Journal:  Neurol Ther       Date:  2015-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.